Open in Screener

PTHS

Pelthos Therapeutics Inc

Apr 06 • 04:00PM ET

24.38

+3.98 19.51 %

Healthcare • Biotechnology • USA • AMEX

Apr 06, 4:01 PMAnalyst optimism and high price targets drive momentum buying in PTHS shares.

Peers: VRTX BMRN SRPT BLUE ALNY IONS NBIX AMGN GILD REGN

Index	-	P/E	-	EPS (ttm)	-20.77	Insider Own	12.84%	Shs Outstand	3.23M	Perf Week	8.40%
Market Cap	81.80M	Forward P/E	-	EPS next Y	-1.04	Insider Trans	-2.87%	Shs Float	2.92M	Perf Month	8.79%
Enterprise Value	98.61M	PEG	-	EPS next Q	-3.45	Inst Own	32.95%	Short Float	2.83%	Perf Quarter	-17.22%
Income	-43.32M	P/S	4.87	EPS this Y	57.58%	Inst Trans	6.00%	Short Ratio	9.91	Perf Half Y	-8.42%
Sales	16.80M	P/B	2.03	EPS next Y	89.40%	ROA	-	Short Interest	0.08M	Perf YTD	-21.35%
Book/sh	12.02	P/C	4.54	EPS next 5Y	-	ROE	-	52W High	54.29 -55.09%	Perf Year	78.77%
Cash/sh	5.37	P/FCF	-	EPS past 3/5Y	-75.48% -82.26%	ROIC	-59.28%	52W Low	9.00 170.89%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- 142.58%	Gross Margin	62.65%	Volatility	10.27% 7.62%	Perf 5Y	-
Dividend TTM	-	EV/Sales	5.87	EPS Y/Y TTM	-12.49%	Oper. Margin	-193.09%	ATR (14)	2.09	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.12	Sales Y/Y TTM	-	Profit Margin	-257.93%	RSI (14)	56.28	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.03	EPS Q/Q	-134.73%	SMA20	7.34%	Beta	4.00	Target Price	57.14
Payout	-	Debt/Eq	0.90	Sales Q/Q	-	SMA50	5.78%	Rel Volume	3.45	Prev Close	20.40
Employees	92	LT Debt/Eq	0.88	Earnings	Mar 19 BMO	SMA200	-2.21%	Avg Volume	8.32K	Price	24.38
IPO	Feb 16, 2024	Option/Short	No / Yes	EPS/Sales Surpr.	-85.84% 3.28%	Trades		Volume	28,715	Change	19.51%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-01-26	Initiated	Cantor Fitzgerald	Overweight	$50
Feb-27-26	Initiated	Piper Sandler	Overweight	$48
Dec-03-25	Initiated	Lake Street	Buy	$50
Dec-03-25	Initiated	H.C. Wainwright	Buy	$60
Nov-25-25	Initiated	Roth Capital	Buy	$57
Sep-02-25	Initiated	Oppenheimer	Outperform	$50

Mar-31-26 08:30AM	Pelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye Pain (GlobeNewswire)
Mar-19-26 03:00PM	Pelthos Therapeutics Inc (PTHS) Q4 2025 Earnings Call Highlights: Prescription Surge and ... (GuruFocus.com)
06:30AM	Pelthos Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Mar-12-26 08:30AM	Pelthos Therapeutics to Present at 38th Annual ROTH Conference (GlobeNewswire)
Mar-09-26 08:30AM	Pelthos Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026 (GlobeNewswire)
08:00AM	Loading…
Feb-23-26 08:00AM	Pelthos Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference (GlobeNewswire) +5.04%
Jan-13-26 08:30AM	Pelthos Therapeutics Secures Up to $50 Million Senior Secured Term Loan Facility from Horizon Technology Finance (GlobeNewswire)
Jan-05-26 07:30AM	Pelthos Therapeutics Acquires Xeglyze (abametapir) Topical Treatment for Head Lice (GlobeNewswire) -9.03%
Dec-23-25 05:57PM	Pelthos Therapeutics Expands Board of Directors with the Appointment of Andrew Einhorn (GlobeNewswire)
Dec-04-25 07:00AM	Pelthos Therapeutics Signs Major Pharmacy Benefit Manager Agreement Expanding Patient Access to ZELSUVMI (berdazimer) Topical Gel, 10.3% (GlobeNewswire)
Dec-02-25 08:00AM	Pelthos Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-13-25 06:45AM	Pelthos Therapeutics Announces Third Quarter Fiscal 2025 Financial Results (GlobeNewswire) -7.27%
Nov-07-25 08:00AM	Pelthos Therapeutics Acquires Xepi (ozenoxacin) Cream, 1% and Announces $18 Million Private Convertible Notes Financing (GlobeNewswire) -8.07%
Nov-05-25 08:00AM	Pelthos Therapeutics to Report Third Quarter 2025 Financial Results on November 13, 2025 (GlobeNewswire) +6.47%
Oct-09-25 08:00AM	Pelthos Therapeutics Launches Moms Against Molluscum Movement to Unite Families Affected by Molluscum Contagiosum (GlobeNewswire) -7.89%
08:30AM	Loading…
Sep-08-25 08:30AM	Pelthos Therapeutics to Participate in Upcoming September Investor Conferences (GlobeNewswire) +13.96%
Sep-02-25 08:00AM	Pelthos Therapeutics to Participate in the 2025 Wells Fargo Healthcare Conference (GlobeNewswire) -5.03%
Aug-18-25 08:00AM	Pelthos Therapeutics Reports Second Quarter 2025 Financial Results for Legacy Operations and Provides Business Update (GlobeNewswire)
Jul-10-25 08:00AM	Pelthos Therapeutics Launches ZELSUVMI (berdazimer) Topical Gel 10.3%, the First and Only FDA-Approved At-Home Treatment for Molluscum Contagiosum (GlobeNewswire) +60.78%
Jul-02-25 07:00AM	Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement (GlobeNewswire) +22.22%
07:00AM	Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics (GlobeNewswire)

Pelthos Therapeutics, Inc. engages in the provision of therapeutic products. It produces products under its proprietary nitic oxide-based technology platform Nitricil. Its main product is a topical gel for the treatment of molluscum contagiosum. The company was founded on March 19, 2021 and is headquartered in Durham, NC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Malamut Richard	Director	Apr 02 '26	Sale	20.92	590	12,340	27,422	Apr 06 05:03 PM
Friedberg Ezra M	Director	Apr 02 '26	Sale	20.92	558	11,671	82,027	Apr 06 05:03 PM
Pauls Matthew	Director	Apr 02 '26	Sale	20.92	786	16,439	15,150	Apr 06 05:02 PM
Greenleaf Peter	Director	Apr 02 '26	Sale	20.92	797	16,670	24,681	Apr 06 05:01 PM
Pauls Matthew	Director	Oct 02 '25	Option Exercise	0.00	2,123	0	10,616	Dec 12 05:01 PM
Pauls Matthew	Director	Jul 02 '25	Option Exercise	0.00	8,493	0	8,493	Dec 12 05:01 PM
Friedberg Ezra M	Director	Nov 25 '25	Sale	28.03	10,000	280,280	30,000	Nov 26 12:37 PM

Open in Screener

SLNO

Soleno Therapeutics Inc

Apr 06 • 04:00PM ET

52.25

+12.76 32.31 %

Healthcare • Biotechnology • USA • NASD

SLNO Soleno Therapeutics Inc daily Stock Chart

Peers: VKTX RZLT MDGL LGND KURA ARDX ASRT ENTA PDSB BTAI

| Held by: XBI VTI IWM VXF IWO SCHA VTWO VHT LABU ITOT

Index	RUT	P/E	234.41	EPS (ttm)	0.22	Insider Own	3.96%	Shs Outstand	52.29M	Perf Week	73.88%
Market Cap	2.70B	Forward P/E	8.06	EPS next Y	6.49	Insider Trans	-0.69%	Shs Float	49.58M	Perf Month	35.47%
Enterprise Value	2.44B	PEG	0.04	EPS next Q	0.68	Inst Own	125.32%	Short Float	18.82%	Perf Quarter	10.77%
Income	20.48M	P/S	14.17	EPS this Y	916.67%	Inst Trans	-0.39%	Short Ratio	5.53	Perf Half Y	-9.88%
Sales	190.41M	P/B	6.07	EPS next Y	63.56%	ROA	4.58%	Short Interest	9.33M	Perf YTD	12.85%
Book/sh	8.61	P/C	8.83	EPS next 5Y	189.28%	ROE	5.89%	52W High	90.32 -42.15%	Perf Year	-22.57%
Cash/sh	5.92	P/FCF	57.81	EPS past 3/5Y	- -	ROIC	4.08%	52W Low	29.43 77.54%	Perf 3Y	2041.39%
Dividend Est.	-	EV/EBITDA	144.05	Sales past 3/5Y	- -	Gross Margin	98.32%	Volatility	8.07% 6.25%	Perf 5Y	185.52%
Dividend TTM	-	EV/Sales	12.84	EPS Y/Y TTM	105.97%	Oper. Margin	7.85%	ATR (14)	3.22	Perf 10Y	-41.46%
Dividend Ex-Date	-	Quick Ratio	5.55	Sales Y/Y TTM	-	Profit Margin	10.75%	RSI (14)	77.80	Recom	2.27
Dividend Gr. 3/5Y	- -	Current Ratio	5.80	EPS Q/Q	162.02%	SMA20	48.01%	Beta	-2.80	Target Price	84.67
Payout	0.00%	Debt/Eq	0.12	Sales Q/Q	-	SMA50	36.93%	Rel Volume	34.42	Prev Close	39.49
Employees	182	LT Debt/Eq	0.12	Earnings	Feb 25 AMC	SMA200	-8.62%	Avg Volume	1.69M	Price	52.25
IPO	Nov 13, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	12.55% 3.36%	Trades		Volume	58,030,994	Change	32.31%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-18-25	Initiated	Wolfe Research	Outperform	$75
Oct-07-25	Initiated	Goldman	Buy	$125
Aug-20-25	Initiated	Wells Fargo	Overweight	$123
Jun-23-25	Initiated	TD Cowen	Buy	$110
Mar-05-25	Resumed	Stifel	Buy	$74
Dec-02-24	Reiterated	Stifel	Buy	$74
Dec-02-24	Reiterated	Robert W. Baird	Outperform	$72
Sep-03-24	Initiated	H.C. Wainwright	Buy	$70
May-10-24	Initiated	Robert W. Baird	Outperform	$72
Feb-05-24	Initiated	Piper Sandler	Overweight	$93
Jan-23-24	Initiated	Stifel	Buy	$63
Nov-21-23	Resumed	Guggenheim	Buy	$40
Sep-29-20	Initiated	Guggenheim	Buy	$8
Jan-10-20	Initiated	Craig Hallum	Buy	$8
Dec-23-19	Initiated	Oppenheimer	Outperform	$10
Feb-13-18	Reiterated	Maxim Group	Buy	$8 → $4

Show Previous Ratings

Apr-06-26 05:30PM	Are SLNO, FORA, AFBI, MKC Obtaining Fair Deals for their Shareholders? (PR Newswire) +32.31%
04:06PM	Oil Climbs, Stocks Whipsaw After Trumps Warning: Markets Wrap (Bloomberg)
03:28PM	Neurocrine Agrees $2.9 Billion Soleno Deal At 34% Premium (GuruFocus.com)
10:30AM	BC-Most Active Stocks (Associated Press)
09:35AM	Neurocrine Biosciences to acquire Soleno Therapeutics in $2.9B deal (Proactive)
08:58AM	Loading…
08:58AM	SLNO Jumps As Deal Buzz Lifts Stocks (GuruFocus.com)
07:34AM	Neurocrine to Buy Soleno for $2.9 Billion (The Wall Street Journal)
07:24AM	This Pharma Stock Is Surging 40%. Neurocrine Is Buying It in $2.9 Billion Deal. (Barrons.com)
07:18AM	Soleno Therapeutics climbs on deal news, and more stocks on the move (MarketWatch)
07:12AM	Neurocrine to buy Soleno Therapeutics for $2.9 billion (Reuters)
07:04AM	Neurocrine wants to develop new obesity drugs. It's reportedly nearing an acquisition to accelerate that move. (MarketWatch)
07:00AM	Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio (PR Newswire)
05:56AM	These Stocks Are Today's Movers: Intel, Micron, Paramount, Strategy, Soleno Therapeutics, and More (Barrons.com)
Apr-01-26 03:43PM	Soleno (SLNO) Sued After DCCR Launch Setback, Share Drop-- Hagens Berman (PR Newswire) +10.48%
Mar-16-26 03:03AM	Soleno Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SLNO (PR Newswire)
09:00AM	Loading…
Mar-12-26 09:00AM	SLNO Lawsuit Alleges Allegedly Conducting Sham Clinical Trials - Soleno Therapeutics, Inc. Investors Face Losses Following Allegedly Conducting Sham Clinical Trials: SueWallSt (PR Newswire) -5.92%
04:40AM	Soleno Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SLNO (PR Newswire)
Mar-10-26 08:00AM	Soleno Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights SLNO (Business Wire)
Mar-09-26 08:31PM	H.C. Wainwright Lowers PT on Soleno (SLNO), Keeps a Buy Rating (Insider Monkey)
Mar-04-26 02:30AM	Soleno Therapeutics, Inc. (SLNO) Revenue Tops Expectations With $91.7M in Q4 Results, TD Cowen Maintains Buy (Insider Monkey)
Mar-01-26 04:27AM	Wells Fargo Cuts PT on Soleno Therapeutics (SLNO) to $110 From $114 - Here's Why (Insider Monkey)
Feb-26-26 12:33PM	Soleno Therapeutics, Inc. Q4 2025 Earnings Call Summary (Moby) -7.12%
08:00AM	Soleno Therapeutics Announces Retirement of James Mackaness and Appointment of Jennifer Fulk as Chief Financial Officer (GlobeNewswire)
03:08AM	Soleno Therapeutics Q4 Earnings Call Highlights (MarketBeat)
12:04AM	Soleno Therapeutics Inc (SLNO) Q4 2025 Earnings Call Highlights: Achieving Profitability and ... (GuruFocus.com)
Feb-25-26 04:01PM	Soleno Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Update on U.S. Launch of VYKAT XR (GlobeNewswire)
Feb-19-26 12:42PM	Rhythm Pharmaceuticals Is Well-Positioned, Analyst Says Could Capture Big Share Of Rare Obesity Market (Benzinga)
Feb-16-26 12:24PM	Soleno Therapeutics (SLNO) Sparks Confidence Amid Topline Outperformance (Insider Monkey)
Feb-15-26 06:39AM	Soleno Therapeutics Updates PWS Launch, Reimbursement Trends and EU Review at Guggenheim Summit (MarketBeat)
Feb-11-26 08:00AM	Soleno Therapeutics to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026, at 4:30 PM ET (GlobeNewswire)
11:03AM	Loading…
Feb-02-26 11:03AM	Ultragenyx Pharmaceutical Resubmits UX111 BLA for Sanfilippo Syndrome (Zacks) +9.75%
09:35AM	Down 18.3% in 4 Weeks, Here's Why Soleno Therapeutics (SLNO) Looks Ripe for a Turnaround (Zacks)
Jan-30-26 10:24AM	FDA Accepts SMMT's Application Seeking Approval for NSCLC Drug (Zacks)
Jan-29-26 08:00AM	Soleno Therapeutics to Participate in Upcoming Conferences (GlobeNewswire)
Jan-27-26 12:59PM	HCA Healthcare Q4 Earnings Beat Estimates on Strong Patient Volumes (Zacks)
07:22AM	Solena Therapeutics (SLNO) Stock Under Pressure But Upside is Huge (Insider Monkey)
Jan-23-26 04:56AM	Is Soleno Therapeutics, Inc. (NASDAQ:SLNO) The Best Under $50 Stock to Buy Now? (Insider Monkey)
Jan-22-26 10:21PM	Soleno Therapeutics Inc. (SLNO): Analysts See Major Upside (Insider Monkey)
Jan-14-26 09:55AM	Soleno Therapeutics (SLNO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Jan-13-26 04:28AM	New Strong Buy Stocks for January 13th (Zacks)
Jan-12-26 07:00AM	Soleno Therapeutics Announces Select Preliminary Fourth Quarter and Full-Year 2025 Results (GlobeNewswire)
Jan-09-26 03:16AM	Soleno Therapeutics (SLNO) Among Stocks That Will Bounce Back According to Analysts (Insider Monkey) -5.49%
Jan-08-26 09:36AM	Zacks Industry Outlook Highlights Soleno Therapeutics, Nektar Therapeutics, Rigel Pharmaceuticals, Ironwood Pharmaceuticals and Marker Therapeutics (Zacks)
Jan-07-26 08:45AM	5 Small Drug Stocks to Buy as Industry Recovery Picks Up (Zacks)
Jan-06-26 08:00AM	Do You Believe in the Growth Prospects of Soleno Therapeutics (SLNO)? (Insider Monkey)
Jan-05-26 08:00AM	Soleno Therapeutics Announces Publication of Results from Pivotal Study of VYKAT XR in the Journal of Clinical Endocrinology and Metabolism (GlobeNewswire)
Dec-11-25 04:27PM	Rhythm Pharma Hits Record High On Unexpected Obesity-Tied Win (Investor's Business Daily) +5.07%
Dec-10-25 10:32AM	Is Soleno Therapeutics, Inc. (SLNO) The Cheap Healthcare Stock To Buy Heading Into 2026? (Insider Monkey)
Dec-03-25 04:05PM	Soleno Therapeutics Announces the Passing of Board Member William G. Harris (GlobeNewswire) +5.41%
Nov-30-25 12:26AM	Analyst Dismisses ViCAT XR Safety Fears, Expects Strong Growth Despite Recent Stock Weakness (Insider Monkey)
Nov-25-25 08:39AM	Soleno Therapeutics (SLNO) Reports Strong Q3 Earnings Despite VYKAT XR Safety Concerns (Insider Monkey) +8.41%
Nov-24-25 08:00AM	Soleno Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-21-25 05:22AM	Wolfe Research Initiates Soleno Therapeutics (SLNO) Coverage with Outperform Rating, $75 PT, Dismisses Patient Slowdown Concerns (Insider Monkey)
Nov-11-25 07:00AM	Soleno Therapeutics Announces Entry Into $100 Million Accelerated Share Repurchase Agreement (GlobeNewswire) +5.16%
Nov-07-25 10:04AM	Soleno Therapeutics (SLNO) Faces Investor Scrutiny Amid Disappointing VYKATÔ XR Starts, Discontinuations; Shares Down 26% -- Hagens Berman (PR Newswire) +9.55%
Nov-06-25 12:07PM	Soleno Therapeutics (SLNO) Ends 26% Lower After Q3 Earnings (Insider Monkey) -7.10%
Nov-05-25 06:26AM	Soleno slumps despite sales uptick; Madrigals MASH drug continues ascent (BioPharma Dive) -26.59%
12:03AM	Soleno Therapeutics Inc (SLNO) Q3 2025 Earnings Call Highlights: Profitability Achieved Amidst ... (GuruFocus.com)
Nov-04-25 04:01PM	Soleno Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on U.S. Launch of VYKAT(TM) XR (GlobeNewswire)
Nov-03-25 07:28AM	Soleno Therapeutics Inc (SLNO) Q3 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
Oct-28-25 08:00AM	Soleno Therapeutics to Participate in Upcoming November Conferences (GlobeNewswire)
Oct-22-25 05:01PM	Soleno Therapeutics, Inc. (SLNO): A Bull Case Theory (Insider Monkey)
Oct-21-25 08:00AM	Soleno Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025, at 4:30 PM ET (GlobeNewswire)
Oct-17-25 09:54PM	Goldman Sachs Initiates Coverage of Soleno Therapeutics (SLNO) With a Buy Rating (Insider Monkey)
Oct-13-25 08:00AM	Soleno Therapeutics Appoints Biopharmaceutical Executive Mark W. Hahn to its Board of Directors (GlobeNewswire)
Oct-07-25 01:05PM	Piper Sandler Maintains a Buy Rating on Soleno Therapeutics (SLNO), Sets a $145 PT (Insider Monkey) +6.26%
Sep-30-25 04:01AM	Wells Fargo Reiterates a Buy Rating on Soleno Therapeutics (SLNO), Sets a PT of $123 (Insider Monkey)
Sep-25-25 10:50AM	ACAD Stock Down 10% Following Phase III Hyperphagia Study Failure (Zacks)
10:23AM	Soleno Therapeutics (SLNO) Jumps 13.46% as Competitor Fails Prader-Willi Treatment Trial (Insider Monkey)
Sep-24-25 04:20PM	Acadia Pharma Tumbles On Failed Genetic Disease Drug; Soleno Surges (Investor's Business Daily) +13.46%
07:28AM	Acadia to scrap Prader-Willi drug after study setback (BioPharma Dive)
Sep-18-25 10:38AM	Soleno Therapeutics, Inc. (SLNO) Targets EMA Approval as U.S. Launch of VYKAT XR Expands (Insider Monkey) +10.98%
Sep-12-25 06:45AM	Takeda poaches top Lilly exec; Maze soars on early PKU drug data (BioPharma Dive) -5.47%
Sep-11-25 09:35AM	Soleno Therapeutics (SLNO) Loses 26% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) -5.49%
02:18AM	Soleno Therapeutics (SLNO) Falls Hard on Patient Death (Insider Monkey)
Sep-10-25 12:59AM	Here's Why Analysts are Bullish on Soleno Therapeutics (SLNO) (Insider Monkey) -14.52%
Aug-27-25 08:00AM	Soleno Therapeutics to Participate in Upcoming September Conferences (GlobeNewswire)
Aug-20-25 04:02PM	Soleno Therapeutics (SLNO) Drops Amid Critical Scorpion Report -- Hagens Berman (PR Newswire)
09:34AM	Nu double upgraded, Novavax downgraded: Wall Street's top analyst calls (The Fly)
Aug-19-25 09:35AM	Down 21.7% in 4 Weeks, Here's Why Soleno Therapeutics (SLNO) Looks Ripe for a Turnaround (Zacks)
Aug-15-25 09:57AM	Soleno Therapeutics stock falls after Scorpion Capital short report (Investing.com) -7.41%
Aug-11-25 09:55AM	How Much Upside is Left in Soleno Therapeutics (SLNO)? Wall Street Analysts Think 43.15% (Zacks)
08:50AM	Here's Why Momentum in Soleno Therapeutics (SLNO) Should Keep going (Zacks)
Aug-06-25 05:10PM	Soleno Therapeutics, Inc. (SLNO) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-28-25 08:00AM	Soleno Therapeutics to Report Second Quarter 2025 Financial Results on August 6, 2025, at 4:30 PM ET (GlobeNewswire)
Jul-25-25 12:00PM	Soleno Therapeutics, Inc. (SLNO) is a Great Momentum Stock: Should You Buy? (Zacks)
Jul-23-25 09:55AM	Can Soleno Therapeutics (SLNO) Climb 33.11% to Reach the Level Wall Street Analysts Expect? (Zacks)
08:50AM	Here's What Could Help Soleno Therapeutics (SLNO) Maintain Its Recent Price Strength (Zacks)
Jul-21-25 12:15AM	Soleno Therapeutics' Vykat XR Exceeds Sales Expectations (Insider Monkey)
Jul-10-25 09:59AM	Soleno sales of new Prader-Willi drug rise faster than expected (BioPharma Dive) -9.23%
09:07AM	Soleno Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock (GlobeNewswire)
06:01AM	Soleno Therapeutics Announces Proposed $200 Million Public Offering of Common Stock (GlobeNewswire)
06:00AM	Soleno Therapeutics Announces Preliminary Financial and Operational Results for the Second Quarter Ended June 30, 2025 (GlobeNewswire)
Jul-01-25 08:00AM	Soleno Therapeutics Announces Two Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ENDO 2025 (GlobeNewswire)
Jun-26-25 03:24PM	TD Cowen Starts Coverage Soleno Therapeutics (SLNO) Stock, Gives Buy (Insider Monkey)
Jun-25-25 08:00AM	Soleno Therapeutics Highlights New Data on VYKAT(TM) XR at the 2025 United in Hope: International Prader-Willi Syndrome Conference (GlobeNewswire)
Jun-23-25 09:38AM	DoorDash, AMD upgraded: Wall Street's top analyst calls (The Fly)
Jun-20-25 08:00AM	Soleno Therapeutics Announces Multiple Presentations at the 2025 United in Hope: International Prader-Willi Syndrome Conference (GlobeNewswire)
May-26-25 09:16AM	EMA validates Solenos application for Prader-Willi syndrome treatment (Pharmaceutical Technology)

Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Manning Meredith	Chief Commercial Officer	Mar 27 '26	Sale	30.44	7,522	228,980	64,507	Mar 31 08:17 PM
Huang Michael F.	Sr. VP of Clinical Development	Mar 27 '26	Sale	30.44	6,582	200,365	39,823	Mar 31 08:15 PM
Abingworth Bioventures VII LP	Shareholder	Aug 11 '25	Proposed Sale	82.15	1,347,522	110,696,581		Aug 15 09:00 PM
Hirano Patricia C	SEE REMARKS	Jul 01 '25	Sale	82.76	3,830	316,971	13,206	Jul 03 04:41 PM
PATRICIA HIRANO	Officer	Jul 01 '25	Proposed Sale	82.76	3,830	316,971		Jul 01 04:03 PM
Hirano Patricia C	SEE REMARKS	Jun 24 '25	Option Exercise	44.25	266	11,770	17,302	Jun 26 06:04 PM
Hirano Patricia C	SEE REMARKS	Jun 24 '25	Sale	84.25	266	22,410	17,036	Jun 26 06:04 PM
PATRICIA HIRANO	Officer	Jun 24 '25	Proposed Sale	84.25	266	22,410		Jun 24 04:07 PM

Open in Screener

SVRA

Savara Inc

Apr 06 • 04:00PM ET

5.60

+0.04 0.72 %

Healthcare • Biotechnology • USA • NASD

Peers: BMRN RARE ARWR NVAX AXSM HRTX ACAD PTGX KPTI CRBP

| Held by: VTI XBI IWM VXF IWO IBB VTWO SCHA LFSC IWC

Index	RUT	P/E	-	EPS (ttm)	-0.53	Insider Own	48.85%	Shs Outstand	204.57M	Perf Week	8.95%
Market Cap	1.15B	Forward P/E	-	EPS next Y	-0.30	Insider Trans	-0.02%	Shs Float	104.69M	Perf Month	2.00%
Enterprise Value	940.30M	PEG	-	EPS next Q	-0.14	Inst Own	53.32%	Short Float	22.45%	Perf Quarter	-0.71%
Income	-118.84M	P/S	-	EPS this Y	12.26%	Inst Trans	18.92%	Short Ratio	14.27	Perf Half Y	60.46%
Sales	0.00M	P/B	5.64	EPS next Y	35.13%	ROA	-50.97%	Short Interest	23.51M	Perf YTD	-7.13%
Book/sh	0.99	P/C	4.86	EPS next 5Y	-	ROE	-63.45%	52W High	7.01 -20.06%	Perf Year	96.49%
Cash/sh	1.15	P/FCF	-	EPS past 3/5Y	-28.87% 8.57%	ROIC	-50.99%	52W Low	1.89 196.30%	Perf 3Y	225.58%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.57% 5.79%	Perf 5Y	171.84%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-10.76%	Oper. Margin	-	ATR (14)	0.30	Perf 10Y	-73.33%
Dividend Ex-Date	-	Quick Ratio	11.85	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	56.33	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	11.85	EPS Q/Q	0.52%	SMA20	5.94%	Beta	0.36	Target Price	10.81
Payout	-	Debt/Eq	0.15	Sales Q/Q	-	SMA50	2.21%	Rel Volume	0.81	Prev Close	5.56
Employees	70	LT Debt/Eq	0.15	Earnings	Mar 13 BMO	SMA200	27.78%	Avg Volume	1.65M	Price	5.60
IPO	Oct 16, 2000	Option/Short	Yes / Yes	EPS/Sales Surpr.	-9.43% -	Trades		Volume	1,337,490	Change	0.72%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-20-25	Initiated	Wells Fargo	Overweight	$7
Aug-15-25	Upgrade	H.C. Wainwright	Neutral → Buy	$5
May-29-25	Downgrade	H.C. Wainwright	Buy → Neutral	$2
Dec-20-24	Initiated	Wells Fargo	Overweight	$8
Nov-13-24	Downgrade	Evercore ISI	Outperform → In-line	$7 → $5
Feb-15-24	Initiated	JMP Securities	Mkt Outperform	$8
Nov-07-23	Initiated	Guggenheim	Buy	$7
May-16-23	Upgrade	Jefferies	Hold → Buy	$2 → $4
Mar-31-23	Downgrade	Jefferies	Buy → Hold	$2
Mar-16-21	Initiated	Piper Sandler	Overweight	$7
Mar-15-21	Initiated	Oppenheimer	Outperform	$4
Jun-13-19	Reiterated	H.C. Wainwright	Buy	$22 → $6
Jun-13-19	Downgrade	Ladenburg Thalmann	Buy → Neutral	$21 → $3
Jun-13-19	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Aug-13-18	Resumed	ROTH Capital	Neutral	$12
Jan-03-18	Initiated	Ladenburg Thalmann	Buy	$35
Sep-27-17	Resumed	ROTH Capital	Buy	$40
Sep-22-17	Initiated	Jefferies	Buy	$20
Sep-11-17	Initiated	JMP Securities	Mkt Outperform	$20

Show Previous Ratings

Mar-30-26 08:05AM	Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) (Business Wire)
Mar-13-26 08:05AM	Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update (Business Wire)
Mar-06-26 04:05PM	Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) (Business Wire)
Mar-04-26 04:05PM	Savara Announces Participation in 2026 Citizens Life Sciences Conference (Business Wire)
Mar-01-26 07:36PM	Savara Highlights FDA Priority Review for Molbreevi as Aug. 22 PDUFA Date Nears (MarketBeat)
04:15PM	Loading…
Feb-20-26 04:15PM	Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) (Business Wire)
Feb-15-26 11:03AM	Savara Eyes August PDUFA for MOLBREEVI as FDA BLA Filing Decision Nears, Execs Say at Summit (MarketBeat)
Feb-13-26 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Feb-04-26 04:05PM	Savara Announces Participation in Upcoming Investor Healthcare Conferences (Business Wire) -5.30%
Jan-27-26 08:05AM	Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI* (Business Wire)
Jan-16-26 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Jan-08-26 04:05PM	PANTHERx Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI* (Business Wire)
Dec-22-25 08:30AM	Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) (Business Wire) +6.94%
Dec-17-25 08:05AM	Savara Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-11-25 08:05AM	Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI* (Business Wire)
08:05AM	Loading…
Dec-02-25 08:05AM	Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow Nebulizer System (Business Wire)
Dec-01-25 01:23PM	Savara (SVRA) Climbs 27.8% Ahead of 2 Health Conferences (Insider Monkey) -7.15%
Nov-20-25 04:05PM	Savara Announces Participation in Upcoming Investor Healthcare Conferences (Business Wire) +5.35%
Nov-12-25 04:05PM	Savara Reports Third Quarter 2025 Financial Results and Provides Business Update (Business Wire)
Nov-03-25 04:05PM	Savara Announces Participation in Upcoming Investor Healthcare Conferences (Business Wire)
02:56AM	Savara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SVRA (PR Newswire)
Oct-31-25 04:05PM	Savara Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $149.5M (Business Wire)
Oct-30-25 11:29PM	What Does Wall Street Think About Savara Inc. (SVRA)? (Insider Monkey)
Oct-29-25 09:43PM	Savara Announces Pricing of $130.0 Million Public Offering of Common Stock and Pre-funded Warrants (Business Wire)
04:07PM	Savara Announces Proposed Public Offering (Business Wire)
04:01PM	Savara announces $75M Royalty Funding Agreement with RTW to Support the Potential Launch of MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) (Business Wire)
11:57AM	Savara Inc. (SVRA) To Present Molgramostim Data in the Fight Against Infections (Insider Monkey)
Oct-17-25 08:05AM	Savara Announces Chief Medical Officer (CMO) Transition (Business Wire)
Oct-13-25 04:59PM	Savara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SVRA (PR Newswire)
Oct-10-25 09:00AM	Savara Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - SVRA (PR Newswire)
07:40AM	Loading…
Oct-07-25 07:40AM	Savara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SVRA (PR Newswire)
Oct-02-25 04:05PM	Savara Announces Encore Presentations of Results From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2025 (Business Wire)
Sep-29-25 02:00AM	Savara Presents New Data From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2025 (Business Wire)
Sep-25-25 04:37PM	Savara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SVRA (PR Newswire)
Sep-24-25 04:25PM	Did You Lose Money on Savara Inc. (SVRA)? Levi & Korsinsky Urges Investors to Act Before November 7, 2025 (Newsfile)
Sep-23-25 10:53AM	Savara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights SVRA (Business Wire)
Sep-20-25 02:43AM	Guggenheim Lifts Savara (SVRA) Price Target on Pulmonary Alveolar Proteinosis Opportunity (Insider Monkey)
Sep-11-25 04:18PM	Investors in Savara Inc. (SVRA): Protect Your Rights - Contact Levi & Korsinsky Before November 7, 2025 (Newsfile) -6.27%
Sep-02-25 09:00AM	Savara Announces New U.S. Health Claims Data Analysis Finds Over 50% Increase in the Estimated Number of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) Patients Compared to Previous Claims Analysis (Business Wire)
Aug-26-25 04:05PM	Savara Announces Participation in Upcoming Investor Healthcare Conferences (Business Wire) +5.41%
Aug-23-25 04:16AM	Savara Inc. (SVRA) Upgraded to Buy After FDA CMC Breakthrough (Insider Monkey)
Aug-20-25 05:15PM	New England Journal of Medicine (NEJM) to Publish Results From Savara's Pivotal Phase 3 IMPALA-2 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) (Business Wire)
Aug-18-25 08:05AM	Savara to Present New Data from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society Congress 2025 (Business Wire)
Aug-13-25 08:05AM	Savara Reports Second Quarter 2025 Financial Results and Provides a Business Update (Business Wire)
Jul-18-25 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
May-27-25 08:05AM	Savara Receives Refusal to File (RTF) Letter From the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) for MOLBREEVI* to Treat Patients With Autoimmune Pulmonary Alveolar Proteinosis (autoimmune PAP) (Business Wire) -31.69%
07:53AM	Biogen strikes RNAi deal with City; Aurion withdraws IPO (BioPharma Dive)
May-23-25 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
May-22-25 09:05AM	Savara Announces Participation in Jefferies Global Healthcare Conference (Business Wire)
May-21-25 11:16AM	Savara Inc. (SVRA): Analysts See 212% Upside Potential (Insider Monkey) -7.18%
May-18-25 02:30PM	Savara Presented New Data From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at American Thoracic Society Conference (ATS) 2025 (Business Wire)
May-13-25 04:05PM	Savara Reports First Quarter 2025 Financial Results and Provides a Business Update (Business Wire)
May-12-25 04:05PM	Savara Announces Participation in the H.C. Wainwright & Co. 3rd Annual BioConnect Investor Conference (Business Wire) +5.59%
May-01-25 04:05PM	Savara Announces Participation in the Upcoming Citizens Life Sciences Conference (Business Wire)
Apr-21-25 11:16AM	Savara: Make-It-Or-Break-It Molbreevi BLA Filing (Seeking Alpha)
Apr-11-25 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire) +10.61%
Apr-07-25 04:05PM	Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcoming Scientific Conferences (Business Wire) -5.45%
Mar-27-25 07:05AM	Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update (Business Wire)
Mar-26-25 04:45PM	Savara Enters Into Non-Dilutive Debt Financing for up to $200M With Hercules Capital (Business Wire)
04:05PM	Savara Completes Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire)
Mar-17-25 08:05AM	Savara to Present New Data From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society International Conference 2025 (Business Wire) +7.66%
Mar-06-25 08:05AM	Savara Announces U.S. Launch of the aPAP ClearPath Dried Blood Spot Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire)
Mar-03-25 04:15PM	Savara Announces Participation in the Leerink Global Healthcare Conference (Business Wire) -6.83%
Feb-14-25 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Jan-30-25 08:39AM	Savara Announces Manuscript on Long-Term Outcomes With Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Published in ERJ Open Research (Business Wire)
Jan-29-25 04:05PM	Savara Announces Participation in Upcoming Healthcare Investor Conferences (Business Wire)
Dec-23-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Dec-18-24 04:05PM	Savara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire) -6.21% +6.95%
Dec-17-24 04:05PM	Savara Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Nov-22-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
08:05AM	Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024 (Business Wire)
Nov-13-24 01:21PM	Evercore Downgrades Savara on Manufacturing Concerns for Lung Disease Drug Candidate (GuruFocus.com) -15.14%
08:05AM	Savara Announces Participation in Upcoming Healthcare Conferences (Business Wire)
Nov-12-24 08:05AM	Savara Reports Third Quarter 2024 Financial Results and Provides Business Update (Business Wire) -5.90%
Nov-04-24 04:05PM	Savara to Present at the Guggenheim Inaugural Healthcare Innovation Conference (Business Wire)
Oct-22-24 08:05AM	Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of The Balancing Act Airing on Lifetime TV (Business Wire)
Oct-18-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire) -5.05%
Oct-01-24 08:05AM	Savara Announces Patient Journey Map for People Living with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Accepted for Poster Presentation at the CHEST 2024 Annual Meeting (Business Wire) -5.90%
Sep-27-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
08:05AM	Savara Announces Expanded Access Program (EAP) for Molgramostim Inhalation Solution (Molgramostim) for Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire)
Sep-24-24 08:05AM	Savara Appoints Braden Parker as Chief Commercial Officer, Effective Immediately (Business Wire)
Sep-23-24 08:05AM	Savara to Host Analyst and Investor Webinar on September 30, 2024 (Business Wire)
Sep-08-24 06:45AM	Savara Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Were Presented at the European Respiratory Society (ERS) Congress 2024 (Business Wire)
Sep-06-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Sep-03-24 04:05PM	Savara to Present at the H.C. Wainwright 26th Annual Global Investment Conference (Business Wire)
Sep-01-24 10:26PM	Savara, Inc. (SVRA): The Best Multibagger Penny Stock of 2025? (Insider Monkey)
Aug-29-24 08:41PM	10 Best Multibagger Penny Stocks of 2025 (Insider Monkey)
Aug-16-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Aug-15-24 08:05AM	Savara to Present New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2024 (Business Wire) +5.87%
Aug-12-24 04:05PM	Savara Reports Second Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Jun-29-24 08:35PM	Did Savara Inc. (SVRA) Receive a Good Rating from Wall Street Analysts in Q1? (Insider Monkey)
06:30PM	10 Best Biotech Penny Stocks to Buy Now (Insider Monkey)
Jun-28-24 08:50AM	Savara Announces Pricing of $100.0 Million Underwritten Offering of Common Stock (Business Wire) +5.77%
Jun-26-24 07:41AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
06:30AM	Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire)
Jun-25-24 08:05PM	Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire)
Jun-19-24 09:00AM	3 Penny Stocks Poised for Major Upside Over the Next 5 Years (InvestorPlace)
Jun-11-24 06:00AM	3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June Edition (InvestorPlace)
May-29-24 08:05AM	Savara to Present at the Jefferies Global Healthcare Conference (Business Wire)
May-21-24 08:20AM	Oppenheimer Adjusts Savara Price Target to $11 From $9.50, Maintains Outperform Rating (MT Newswires)

Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in December 1995 and is headquartered in Langhorne, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lowrance David L	Chief Financial Officer	Mar 18 '26	Option Exercise	1.60	366,747	588,455	552,550	Mar 20 04:16 PM
McCracken Joseph S	Director	Feb 16 '26	Option Exercise	1.76	1,807	3,180	302,644	Feb 17 05:30 PM
RAMSAY DAVID A	Director	Dec 19 '25	Sale	6.06	20,000	121,220	2,533,642	Dec 19 05:00 PM
RAMSAY DAVID A	Director	Dec 18 '25	Proposed Sale	6.11	20,000	122,200		Dec 18 11:17 AM
Elam Nevan C	Director	Dec 02 '25	Option Exercise	1.46	5,860	8,556	68,360	Dec 04 06:55 PM
Hawkins Richard J	Director	Nov 14 '25	Option Exercise	1.46	5,860	8,556	121,326	Nov 17 04:38 PM
Hawkins Richard J	Director	Jun 20 '25	Buy	2.04	48,225	98,572	115,466	Jun 23 02:39 PM
McCracken Joseph S	Director	May 29 '25	Buy	2.08	10,000	20,825	260,837	Jun 02 07:59 AM

PTHS

Pelthos Therapeutics Inc

SLNO

Soleno Therapeutics Inc

SVRA

Savara Inc

Upgrade your Finviz experience